<DOC>
	<DOCNO>NCT03027245</DOCNO>
	<brief_summary>Study E7389-M044-504 observational , post-authorization , single-arm , prospective , multicenter cohort study conduct characterize determine incidence eribulin-induced peripheral neuropathy ( PN ) , frequency time resolution eribulin-induced PN participant treat eribulin real-life set locally advance metastatic breast cancer follow one two prior chemotherapeutic regimen advance disease .</brief_summary>
	<brief_title>Incidence Resolution Eribulin-Induced Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<criteria>Locally advanced metastatic breast cancer eligible treatment eribulin accord Fachinformation ( German equivalent Summary Product Characteristics ) Maximum two prior chemotherapeutic regimen advance disease Age â‰¥18 year time Informed Consent Ability understand willingness respond question related health Decision participant start treatment eribulin make prior inclusion study . Signed write Informed Consent Previous treatment eribulin line treatment Contraindication accord Fachinformation eribulin Pregnancy lactation Participation interventional clinical trial time</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>locally advanced metastatic breast cancer</keyword>
	<keyword>peripheral neuropathy</keyword>
	<keyword>chemotherapy-induced peripheral neuropathy</keyword>
	<keyword>eribulin</keyword>
</DOC>